Singapore, Aug. 27 -- US-based Celularity Inc., a longevity-focused regenerative and cellular medicine company, and Singaporean startup MuseCell Innovations(R) (MCI), the owner of the Dezawa MuseCell (DMC) platform, have announced an additional US-based manufacturing collaboration under which Celularity will undertake activities to establish US production of Dezawa MuseCells at Celularity's Florham Park, New Jersey facility.

The initial programme is designed to establish manufacturing capability for MCI-authenticated DMC preparations. Under the MCI platform, a preparation is authenticated as a DMC product through perinatal, bone marrow or adipose qualified starting material, manufactured under the licensed Dezawa Method and conformance t...